Next-Step Strategies for Patients Not Responding to GLP-1 Therapy When patients truly fail to respond to GLP-1 therapy, clinicians have several options
14.6 Glycemic Control Trial in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus The efficacy and safety of BYDUREON 2 mg given subcutaneously once weekly or placebo was evaluated in a 24-week randomized, double-blind, placebo-controlled, parallel-group study (Trial 9 - NCT01554618) in 82 patients aged 10 to 17 years with type 2 diabetes treated with diet and exercise alone or in combination with a stable dose of oral antidiabetic agents and/or insulin
FIGURE 1 In K cells, regulatory factor X6 (Rfx6) is a transcription factor that binds to the Gip promoter to increase Gip mRNA expression (Suzuki et al., 2013)
Frontier Peptide Labs 5-Amino-1MQ Capsules are intended exclusively for laboratory research and development purposes
Set up a virtual consultation with one of SpaDermas licensed Nurse Practitioners to find the right supplement for your body, lifestyle, and goals
Duran H, Cardenas-Camarena L, Bayter-Marin JE, Ramos-Gallardo G, Robles-Cervantes JA